m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer

作者：Zihao Feng, Yanping Liang, Junjie Cen, Haohua Yao, Haishan Lin, Jiaying Li, Hui Liang, Zhu Wang, Qiong Deng, Jiazheng Cao, Yong Huang, Jinhuan Wei, Junhang Luo, Wei Chen, Zhenhua Chen · 发表于：Journal of Translational Medicine · 年份：2022 · DOI：10.1186/s12967-022-03711-1 · 被引用次数：71 · 研究领域：RNA modifications and cancer、Cancer-related molecular mechanisms research、interferon and immune responses

BACKGROUND: N6-methyladenosine (m6A) related long noncoding RNAs (lncRNAs) may have prognostic value in bladder cancer for their key role in tumorigenesis and innate immunity. METHODS: Bladder cancer transcriptome data and the corresponding clinical data were acquired from the Cancer Genome Atlas (TCGA) database. The m6A-immune-related lncRNAs were identified using univariate Cox regression analysis and Pearson correlation analysis. A risk model was established using least absolute shrinkage and selection operator (LASSO) Cox regression analyses, and analyzed using nomogram, time-dependent receiver operating characteristics (ROC) and Kaplan-Meier survival analysis. The differences in infiltration scores, clinical features, and sensitivity to Talazoparib of various immune cells between low- and high-risk groups were investigated. RESULTS: Totally 618 m6A-immune-related lncRNAs and 490 immune-related lncRNAs were identified from TCGA, and 47 lncRNAs of their intersection demonstrated prognostic values. A risk model with 11 lncRNAs was established by Lasso Cox regression, and can predict the prognosis of bladder cancer patients as demonstrated by time-dependent ROC and Kaplan-Meier analysis. Significant correlations were determined between risk score and tumor malignancy or immune cell infiltration. Meanwhile, significant differences were observed in tumor mutation burden and stemness-score between the low-risk group and high-risk group. Moreover, high-risk group patients were m...